1. Home
  2. LI vs ILMN Comparison

LI vs ILMN Comparison

Compare LI & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Li Auto Inc.

LI

Li Auto Inc.

SELL

Current Price

$11.56

Market Cap

11.7B

ML Signal

SELL

Logo Illumina Inc.

ILMN

Illumina Inc.

SELL

Current Price

$197.79

Market Cap

37.0B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
LI
ILMN
Founded
2015
1998
Country
China
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.7B
37.0B
IPO Year
2019
2000

Fundamental Metrics

Financial Performance
Metric
LI
ILMN
Price
$11.56
$197.79
Analyst Decision
Buy
Buy
Analyst Count
24
21
Target Price
$14.96
★ $261.45
AVG Volume (30 Days)
★ 2.7M
2.1M
Earning Date
11-25-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 170.87
EPS
N/A
★ 3.65
Revenue
N/A
★ $4,343,000,000.00
Revenue This Year
$0.35
$6.61
Revenue Next Year
$24.93
$7.00
P/E Ratio
★ $29.50
$57.08
Revenue Growth
★ N/A
N/A
52 Week Low
$10.67
$112.65
52 Week High
$20.09
$309.35

Technical Indicators

Market Signals
Indicator
LI
ILMN
Relative Strength Index (RSI) 48.58 32.66
Support Level $10.79 $182.76
Resistance Level $11.95 $201.83
Average True Range (ATR) 0.30 13.28
MACD 0.02 -4.90
Stochastic Oscillator 35.05 1.65

Price Performance

Historical Comparison
LI
ILMN

About LI Li Auto Inc.

Li Auto is one of China's leading new energy vehicle manufacturers. Founded in 2015, the company designs, develops, manufactures, and sells premium smart NEVs with a particular focus on family size premium SUVs and MPVs. Li Auto started volume production of its first model—the Li One, an SUV that is a premium plug-in electric vehicle- in November 2019. Besides PHEVs, its product portfolio now extends to EVs that are fully battery-powered, reaching a wide audience. It has sold over 400,000 NEVs in 2025, accounting for about 3% of China's passenger NEV market.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: